Fibroblast-Activation Protein PET and Histopathology in a Single-Center Database of 324 Patients and 21 Tumor EntitiesNader Hirmas, Wolfgang P. Fendler, Hans‐Ulrich Schildhaus et al.|Journal of Nuclear Medicine|2022Cited by 68
<sup>68</sup>Ga-Labeled Fibroblast Activation Protein Inhibitor (<sup>68</sup>Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the<sup>68</sup>Ga-FAPI PET Observational TrialLukas Kessler, Jens T. Siveke, Nader Hirmas et al.|Journal of Nuclear Medicine|2023Cited by 34
Diagnostic Accuracy of<sup>68</sup>Ga-FAPI Versus<sup>18</sup>F-FDG PET in Patients with Various MalignanciesNader Hirmas, Wolfgang P. Fendler, Rainer Hamacher et al.|Journal of Nuclear Medicine|2024Cited by 31
[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trialKim M. Pabst, Wolfgang P Fendler, Manuel Weber et al.|The Lancet Oncology|2025Cited by 30
<sup>90</sup>Y-FAPI-46 Theranostics Leads to Near-Complete Metabolic Response in 3 Patients with Solitary Fibrous TumorsHelena Lanzafame, Rainer Hamacher, Christoph E. Heilig et al.|Journal of Nuclear Medicine|2025Cited by 10